Sanofi-Aventis returns rights to Taiho anticancer
This article was originally published in Scrip
Executive Summary
Sanofi-Aventishas returned to originator Taiho Pharmaceutical the global rights to the oral anticancer S-1 (TS-1), pointing to new results from a Phase III trial in gastric cancer.